Drug General Information (ID: DDIVX79LT4)
Drug Name			Primaquine		Drug Info		Aurothioglucose		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antimalarial Agents				Antirheumatics
Structure

Mechanism of Primaquine-Aurothioglucose Interaction (Severity Level: Major)
Additive myelosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Primaquine				Aurothioglucose
Mechanism		Myelosuppressive effects				Myelosuppressive effects
Key Mechanism Factor 1
		Factor Name		Myelosuppressive effects
		Factor Description		Myelosuppression, also known as bone marrow suppression, is a decrease in bone marrow activity that leads to a decrease in the production of blood cells. Some blood cell disorders include: erythrocytopenia (anemia), leukopenia (neutropenia), and thrombocytopenia (thrombocytopenia).
Mechanism Description		Additive myelosuppressive effects by the combination of Primaquine and Aurothioglucose

Recommended Action
Management		Concomitant use is generally considered to be contraindicated. Caution should be exercised if these drugs must be used together.

References
1	Product Information. Myochrysine (gold sodium thiomaleate). Merck &amp Co, Inc, West Point, PA.
2	Product Information. Ridaura (auranofin). SmithKline Beecham, Philadelphia, PA.
3	Product Information. Solganal (aurothioglucose). Schering Laboratories, Kenilworth, NJ.